Cannabics Pharmaceuticals Announces Conclusion of Clinical Trial on Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS)
TEL AVIV, Israel and BETHESDA, Maryland, July 3, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), leader in personalized cannabis medicine focused on cancer and its side effects, announced today that it has concluded its clinical trial held at Rambam Medical Center. The Oncology Center at Rambam Medical Center is recognized by the European Society for Medical Oncology (ESMO) as a designated Center of Integrated Oncology and Palliative Care.
Launched in 2016, the study involved patients with advanced Cancer and Cancer Anorexia Cachexia Syndrome (CACS) with Cannabics SR 5mg, daily for 3 months. The main endpoints that were examined were weight gain, appetite and Quality of Life (QOL). The official results are now being evaluated by the Hospital and we expect them to be published in the next few months according to Professor Gil Bar-Sela, who ran the study and is Deputy Director of the Division of Oncology at Rambam Health Care Campus, Head of the Palliative and Supportive Oncology Unit, and Head of the service for Melanoma and Sarcoma patients.
The study is registered with the US NIH under "Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients", Identifier NCT02359123, and may be found at https://clinicaltrials.gov/ct2/show/NCT02359123
Eyal Ballan, Chief Technical Officer of Cannabics Pharmaceuticals said: "We are very pleased to have completed this study. We are awaiting the results and expect them to further elucidate an important aspect of our mission in integrating cannabinoid-based therapies into the world of precision medicine; while at the same time focusing our efforts on bringing scientific data to support developments of cannabinoid-based therapies".
About Cannabics Pharmaceuticals:
Cannabics Pharmaceuticals Inc. (CNBX) is a United States-based public company that is developing cannabinoid-based medicine and treatments focused on cancer and its side effects. Cannabics' approach can be used to develop cannabinoid-based therapies as preventive or primary cancer treatments - not just palliative, the way it's being used now. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move medical cannabinoids into the mainstream of cancer therapies. The company's R&D is based in Israel, where it is licensed to conduct scientific and clinical research on harnessing the therapeutic properties of cannabinoid formulations. For more information, please visit www.cannabics.com.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on April 6th, 2018. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
View original content:http://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-announces-conclusion-of-clinical-trial-on-cannabics-sr-5mg-for-cancer-anorexia-cachexia-syndrome-cacs-300675833.html
SOURCE Cannabics Pharmaceuticals Inc.